C
Cellular Biomedicine Group (CBMG)
A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group (CBMG), which rebranded as AbelZeta Pharma, Inc. in November 2023, is a clinical-stage biopharmaceutical firm focused on developing cell therapies for cancer and autoimmune diseases. The company was founded in 2009 by a team of Chinese-American executives and scientists. A key figure in its history is Dr. Wei (William) Cao, one of the founding executives who joined in 2010 and later became CEO. Another pivotal leader is Tony (Bizuo) Liu, who, with a robust background in finance and corporate strategy from roles at Microsoft and Alibaba, joined CBMG's board in 2013, became CFO in 2014, and has served as CEO since 2016. After trading on NASDAQ, the company completed a privatization process in February 2021, led by a consortium including company management and several investment funds.
The company's business model is centered on its proprietary cell-based technology platforms, particularly Chimeric Antigen Receptor T-cell (CAR-T) and Tumor-Infiltrating Lymphocyte (TIL) therapies. Revenue is primarily generated through strategic licensing, collaboration agreements, and milestone payments with major pharmaceutical companies. A landmark event was a May 2023 global collaboration with Janssen Biotech (a Johnson & Johnson company), which included a $245 million upfront payment to develop and commercialize next-generation CAR-T therapies. The company also has manufacturing and supply agreements, such as one with Novartis for the CAR-T therapy Kymriah in China. CBMG operates state-of-the-art GMP-certified manufacturing facilities in both Rockville, Maryland, and Shanghai to support its clinical trials in the U.S. and China.
CBMG’s product pipeline targets treatments for various cancers and degenerative diseases. A leading candidate is C-CAR039, a bispecific CAR-T therapy targeting CD19 and CD20 for B-cell malignancies, which has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA. Another key product is C-CAR066, an anti-CD20 CAR-T therapy. The company is also developing treatments for solid tumors, such as AFP TCR-T for liver cancer and TIL therapies for non-small cell lung cancer. Previously, its portfolio included stem cell therapies for Knee Osteoarthritis, such as AlloJoin® and ReJoin®, which were later spun off to sharpen the company's focus on immune-oncology.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2021 | $120M | $480M | CICC · GIC · TF Capital · Sequoia | — |
| POST IPO EQUITYOther financing | Feb 2018 | $31M | — | Sailing Capital | — |
Growth signals
Latest recorded traffic for Cellular Biomedicine Group (CBMG) is 180 monthly website visits, down 40% over the last three months. Cellular Biomedicine Group (CBMG)'s team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cellular Biomedicine Group (CBMG) in the North Potomac ecosystem
The Cellular Biomedicine Group (CBMG) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Series B and later1 investor entered at this stage
Sailing Capital
Other known investors1 additional known investor
Funcity Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellular Biomedicine Group (CBMG) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellular Biomedicine Group (CBMG)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.















